Property, Plant and Equipment Disclosure
Asset Age Ratios (Summary)
Average Age
Estimated Total Useful Life
Estimated Age, Time Elapsed Since Purchase
Estimated Remaining Life

Regeneron Pharmaceuticals Inc., balance sheet: property, plant and equipment

US$ in thousands

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Building and improvements	2,423,100)	2,270,000)	2,088,500)	1,891,100)	1,683,400)
Leasehold improvements	133,900)	114,300)	113,900)	100,500)	97,600)
Laboratory equipment	1,384,500)	1,315,300)	1,225,500)	1,038,600)	850,700)
Computer equipment and software	389,700)	337,400)	291,500)	226,300)	183,700)
Furniture, office equipment, and other	165,900)	150,200)	145,200)	130,500)	121,800)
Land	283,100)	264,500)	248,000)	241,200)	230,800)
Construction in progress	1,345,000)	980,500)	767,700)	724,500)	644,800)
Property, plant, and equipment, gross	6,125,200)	5,432,200)	4,880,300)	4,352,700)	3,812,800)
Accumulated depreciation and amortization	(1,978,800)	(1,669,200)	(1,398,100)	(1,131,100)	(922,400)
Property, plant, and equipment, net	4,146,400)	3,763,000)	3,482,200)	3,221,600)	2,890,400)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Download chart

Item	Description	The company
Property, plant, and equipment, gross	Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.	Regeneron Pharmaceuticals Inc. property, plant, and equipment, gross increased from 2021 to 2022 and from 2022 to 2023.
Property, plant, and equipment, net	Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.	Regeneron Pharmaceuticals Inc. property, plant, and equipment, net increased from 2021 to 2022 and from 2022 to 2023.

Regeneron Pharmaceuticals Inc., asset age ratios

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Average age ratio	33.87%	32.30%	30.18%	27.51%	25.75%
Estimated total useful life (years)	18	17	16	18	17
Estimated age, time elapsed since purchase (years)	6	5	5	5	4
Estimated remaining life (years)	12	12	12	13	13

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Download chart

Asset age ratio	Description	The company
Average age ratio	As long as straight-line depreciation is used, this is an accurate estimate of asset age as a percentage of depreciable life. The relative age is a useful measure of whether the company fixed asset base is old or new. Newer assets are likely to be more efficient.	Regeneron Pharmaceuticals Inc. average age ratio of depreciable property, plant and equipment deteriorated from 2021 to 2022 and from 2022 to 2023.
Estimated total useful life	Over longer time periods, this ratio is a useful measure of company depreciation policy and can be used for comparisons with competitors.	Regeneron Pharmaceuticals Inc. estimated total useful life of depreciable property, plant and equipment increased from 2021 to 2022 and from 2022 to 2023.
Estimated time elapsed since purchase	The approximate age in years of a company fixed assets. Useful for comparison purposes.	Regeneron Pharmaceuticals Inc. estimated time elapsed since purchase of depreciable property, plant and equipment deteriorated from 2021 to 2022 and from 2022 to 2023.
Estimated remaining life		Regeneron Pharmaceuticals Inc. estimated remaining life of depreciable property, plant and equipment increased from 2021 to 2022 and from 2022 to 2023.

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selected Financial Data (US$ in thousands)
Accumulated depreciation and amortization	1,978,800)	1,669,200)	1,398,100)	1,131,100)	922,400)
Property, plant, and equipment, gross	6,125,200)	5,432,200)	4,880,300)	4,352,700)	3,812,800)
Land	283,100)	264,500)	248,000)	241,200)	230,800)
Asset Age Ratio
Average age¹	33.87%	32.30%	30.18%	27.51%	25.75%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

2023 Calculations

¹ Average age = 100 × Accumulated depreciation and amortization ÷ (Property, plant, and equipment, gross – Land)
= 100 × 1,978,800 ÷ (6,125,200 – 283,100) = 33.87%

Download chart

Asset age ratio	Description	The company
Average age	As long as straight-line depreciation is used, this is an accurate estimate of asset age as a percentage of depreciable life. The relative age is a useful measure of whether the company fixed asset base is old or new. Newer assets are likely to be more efficient.	Regeneron Pharmaceuticals Inc. average age ratio of depreciable property, plant and equipment deteriorated from 2021 to 2022 and from 2022 to 2023.

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selected Financial Data (US$ in thousands)
Property, plant, and equipment, gross	6,125,200)	5,432,200)	4,880,300)	4,352,700)	3,812,800)
Land	283,100)	264,500)	248,000)	241,200)	230,800)
Depreciation and amortization expense on property, plant, and equipment	328,800)	303,900)	281,100)	230,800)	205,200)
Asset Age Ratio (Years)
Estimated total useful life¹	18	17	16	18	17

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

2023 Calculations

¹ Estimated total useful life = (Property, plant, and equipment, gross – Land) ÷ Depreciation and amortization expense on property, plant, and equipment
= (6,125,200 – 283,100) ÷ 328,800 = 18

Download chart

Asset age ratio	Description	The company
Estimated total useful life	Over longer time periods, this ratio is a useful measure of company depreciation policy and can be used for comparisons with competitors.	Regeneron Pharmaceuticals Inc. estimated total useful life of depreciable property, plant and equipment increased from 2021 to 2022 and from 2022 to 2023.

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selected Financial Data (US$ in thousands)
Accumulated depreciation and amortization	1,978,800)	1,669,200)	1,398,100)	1,131,100)	922,400)
Depreciation and amortization expense on property, plant, and equipment	328,800)	303,900)	281,100)	230,800)	205,200)
Asset Age Ratio (Years)
Time elapsed since purchase¹	6	5	5	5	4

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

2023 Calculations

¹ Time elapsed since purchase = Accumulated depreciation and amortization ÷ Depreciation and amortization expense on property, plant, and equipment
= 1,978,800 ÷ 328,800 = 6

Download chart

Asset age ratio	Description	The company
Estimated time elapsed since purchase	The approximate age in years of a company fixed assets. Useful for comparison purposes.	Regeneron Pharmaceuticals Inc. estimated time elapsed since purchase of depreciable property, plant and equipment deteriorated from 2021 to 2022 and from 2022 to 2023.

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selected Financial Data (US$ in thousands)
Property, plant, and equipment, net	4,146,400)	3,763,000)	3,482,200)	3,221,600)	2,890,400)
Land	283,100)	264,500)	248,000)	241,200)	230,800)
Depreciation and amortization expense on property, plant, and equipment	328,800)	303,900)	281,100)	230,800)	205,200)
Asset Age Ratio (Years)
Estimated remaining life¹	12	12	12	13	13

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

2023 Calculations

¹ Estimated remaining life = (Property, plant, and equipment, net – Land) ÷ Depreciation and amortization expense on property, plant, and equipment
= (4,146,400 – 283,100) ÷ 328,800 = 12

Download chart

Asset age ratio	Description	The company
Estimated remaining life		Regeneron Pharmaceuticals Inc. estimated remaining life of depreciable property, plant and equipment increased from 2021 to 2022 and from 2022 to 2023.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Analysis of Property, Plant and Equipment

Property, Plant and Equipment Disclosure

Asset Age Ratios (Summary)

Average Age

Estimated Total Useful Life

Estimated Age, Time Elapsed since Purchase

Estimated Remaining Life